

Indian Pharmacopoeia Commission and United States Pharmacopoeia Extends Their Collaboration for Promotion of Quality Medicines

The Indian Pharmacopoeia Commission (IPC), an autonomous institute setup under the Ministry of Health and Family Welfare, Government of India and the United States Pharmacopoeia (USP) Convention agreed to extend their Memorandum of Understanding (MoU) for additional terms of two years. Both parties signed for the renewal of the existing MoU during the meeting held at the Ministry of Health and Family Welfare (MoHFW), Nirman Bhawan, New Delhi on 18th November, 2019 in presence of Sh. Arun Singhal, Special Secretary, MoHFW, Dr. Mandeep Kumar Bhandari, Joint Secretary (R), MoHFW, Sh. Rajiv Wadhawan, Director (Drugs), and Dr. V. G. Somani, Drugs Controller General (India). By renewal of this MoU, both parties agreed to:

- Understand the need for increasing awareness of the importance of quality, safety, and efficacy of medicines;
- Recognize the importance of developing long term strategies to ensure that medicines of assured quality, efficacy, and safety are made available to individuals in the United States and India;
- Share a common goal of promoting the quality of medicines



Signing of the Renewal of MoU by Dr. Jai Prakash, Senior Principal Scientific Officer, IPC and Dr. Surendra Nath Koduru, Senior Vice President, USP in Presence of Sh. Arun Singhal, Special Secretary, MoHFW, Dr. Mandeep Kumar Bhandari, Joint Secretary (R), MoHFW, Sh. Rajiv Wadhawan, Director (Drugs), and Dr. V. G. Somani, Drugs Controller General (India) and USP Team